You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.
SBC: KIROMIC BIOPHARMA INC Topic: NHLBIAtheroSclerotic CardioVascular DiseaseASCVDis caused by inflammation within arteriesWhite blood cells enter the arterial wallsmacrophages become engorged with lipid cholesterol and summon other inflammatory cells to form plaques which ultimately rupture or occlude the arterykilling down stream tissuee gheart attackASCVD remains a major cause of morbidity and mortality of the elderlyCoronary artery ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Nitric Oxide Microfluidic Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDDESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIAIn the USthe number of individuals agedand older will increase byover the next decadeConcurrentlyMedicare costs are expected to double to treat chronic diseases that will plague this increasing number of older adultsOne of the most wide spread chronic diseases that affects older adults is sarcopeniawhich is observed inof adults overyears of age andof adults overyears of ageThis disease is characte ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development and Production of Standardized Reference Diets for Zebrafish Research
SBC: Meridian Biotech, LLC Topic: 101The over arching goal of this Phase I SBIR proposal is to begin to optimize and implement standard reference diets for the ZebrafishDanio rerioan animal model of critical importance to the understanding of human health and development of vertebrate organismsA key problem in the industry is that standardized diets or feed management strategies have not been developed for Danio rerioThese diets are ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Reactor for Insect Cell Culture
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: 300This fast track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological researchGlycan Therapeutics is a biotech company specializing in synthesizing sulfated carbohydrates using innovative enzyme based methodsThis proposal is focused on the synthesis of large authentic oligosaccharides in the size range ofmers tomersas w ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections
SBC: Arrevus, Inc. Topic: NIAIDProject SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Chemical Libraries Targeting Epigenetic Methyl Writers and Erasers
SBC: Epicypher, Inc. Topic: 102PROJECT SUMMARYIn this proposalEpiCypher is partnering with DrJian Jina leader in medicinal chemistry and epigenetic drug discoveryto develop the first epigenetics focused chemical library for histone methylationSmall molecule inhibitors that target histone methylation are an emerging class of therapeutics for cancer treatmentThis hot bed of drug development is fueled by the identification of nume ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Fluorescent nanofoldamers for multiplex flow cytometry
SBC: Nirvana Sciences, Inc. Topic: 400PROJECT SUMMARY ABSTRACT Polychromatic flow cytometryFCis one of the most powerful analytical techniques used in immunologybasic researchand clinical medicineIn basic researchFC is a primary tool for understanding disease development at the cellular and subcellular levelsIn the rapidly developing field of immunotherapyFC is an indispensable tool for monitoring the effectiveness of new therapies an ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes
SBC: RIDGELINE THERAPEUTICS LLC Topic: NIDDKABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health